Premium Nahrungsergänzungsmittel | artgerecht

Haemophilus parainfluenzae – Bacterium, Infections and Treatment

Haemophilus parainfluenzae is a gram-negative bacterium that is part of the normal oral flora but can cause serious infections such as endocarditis or respiratory disease.

Regular tips about health Regular tips about health

Things worth knowing about "Haemophilus parainfluenzae"

Haemophilus parainfluenzae is a gram-negative bacterium that is part of the normal oral flora but can cause serious infections such as endocarditis or respiratory disease.

What is Haemophilus parainfluenzae?

Haemophilus parainfluenzae is a gram-negative, facultatively anaerobic rod-shaped bacterium belonging to the family Pasteurellaceae. It is a natural commensal of the human oropharynx and upper respiratory tract. Although it is typically harmless in healthy individuals, it can cause serious infections under certain conditions – particularly in immunocompromised patients or those with pre-existing heart disease.

Occurrence and Transmission

The bacterium colonizes the mucosal surfaces of the oropharynx in a large proportion of the healthy population. Transmission occurs primarily through:

Droplet infection (e.g., coughing, sneezing)
Direct contact with infected mucous membranes
Endogenous spread from the individual's own flora when host defenses are impaired

Diseases Caused by Haemophilus parainfluenzae

In most cases, colonization is asymptomatic. However, in certain risk groups, the bacterium can act as a pathogen and cause the following conditions:

Infective endocarditis: One of the most frequent and severe manifestations, especially in patients with pre-damaged heart valves. H. parainfluenzae belongs to the so-called HACEK group (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella), known for causing slow-growing endocarditis.
Respiratory tract infections: Bronchitis, pneumonia, and exacerbations of chronic obstructive pulmonary disease (COPD)
Sinusitis: Inflammation of the paranasal sinuses
Otitis media: Middle ear infection, especially in children
Meningitis: Inflammation of the meninges (rare, mainly in immunocompromised individuals)
Septic arthritis: Joint infection
Urinary tract infections: Rare, primarily in immunosuppressed patients

Symptoms

Symptoms depend largely on the site of infection:

Endocarditis: Fever, night sweats, fatigue, heart murmur, weight loss
Respiratory infections: Cough, sputum production, shortness of breath, fever
Sinusitis: Facial pain, nasal congestion, headache
Otitis media: Ear pain, hearing loss, fever in children

Diagnosis

Diagnosis of Haemophilus parainfluenzae infection is established through microbiological investigations:

Blood culture: The gold standard when endocarditis or bacteremia is suspected; the organism grows slowly and often requires prolonged incubation times
Swab and culture: From throat secretions, sputum, sinus aspirate, or middle ear fluid
PCR (polymerase chain reaction): Molecular testing for rapid identification
Echocardiography: When endocarditis is suspected, to detect vegetations on heart valves
Antibiogram: To determine antibiotic susceptibility, as resistance – particularly to ampicillin via beta-lactamase production – is possible

Treatment

Therapy depends on the site of infection and the resistance profile of the pathogen:

Antibiotic Therapy

Amoxicillin-clavulanate: Drug of choice for beta-lactamase-producing strains
Third-generation cephalosporins (e.g., ceftriaxone): Commonly used for severe infections such as endocarditis or meningitis
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin): Alternative for patients with beta-lactam intolerance
Ampicillin: Used when susceptibility is confirmed (non-beta-lactamase-producing strains)

Duration of Treatment

For endocarditis, treatment typically lasts four to six weeks with intravenous antibiotics. For uncomplicated respiratory tract infections, a shorter course of seven to fourteen days is standard.

Surgical Intervention

In cases of severe endocarditis with significant heart valve damage or treatment-refractory infection, surgical intervention (valve replacement) may be necessary.

Risk Factors

Certain groups are at increased risk for invasive infections caused by H. parainfluenzae:

Patients with pre-existing heart valve disease
Immunocompromised individuals (e.g., HIV patients, chemotherapy patients)
Elderly individuals
Patients with COPD or other chronic lung diseases
Premature infants and neonates

Distinction from Haemophilus influenzae

Haemophilus parainfluenzae is frequently confused with Haemophilus influenzae. A key microbiological difference lies in growth factor requirements: while H. influenzae requires both factor X (hemin) and factor V (NAD), H. parainfluenzae only requires factor V. An effective vaccine exists against H. influenzae type b (the Hib vaccine), but no vaccine is currently available for H. parainfluenzae.

References

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th Edition, Elsevier (2020)
European Society of Cardiology (ESC) – Guidelines on Infective Endocarditis (2023). Available at: https://www.escardio.org
Petti CA et al. – HACEK Endocarditis: Characteristics and Outcomes. PubMed, Journal of Clinical Microbiology (2018). Available at: https://pubmed.ncbi.nlm.nih.gov

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category